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Abstract
Purpose—To determine long-term oncologic outcomes of radical prostatectomy (RP) after 
neoadjuvant chemo-hormonal therapy for clinically localized, high-risk prostate cancer.
Methods—In this phase II multicenter trial of patients with high-risk prostate cancer 
(PSA>20ng/ml, Gleason ≥8, or clinical stage ≥T3), androgen deprivation therapy (goserelin 
acetate depot) and paclitaxel, carboplatin and estramustine were administered prior to RP. We 
report the long-term oncologic outcomes of these patients and compared them to a contemporary 
cohort who met oncologic inclusion criteria but received RP only.
Results—Thirty-four patients were enrolled in this study and followed for a median of 13.1 
years. Within 10 years most patients experienced biochemical recurrence (BCR-free probability= 
22%; 95% CI 10%, 37%). However the probability of disease-specific survival at 10 years was 
84% (95% CI 66%, 93%) and overall survival was 78% (95% CI 60%, 89%). The chemohormonal 
therapy group had higher-risk features than the comparison group (N=123 patients) with an almost 
doubled risk of calculated preoperative 5-year BCR (69% vs 36%, p<0.0001). After adjusting for 
these imbalances the CHT group had trends toward improvement in BCR (HR 0.76, 95% CI 0.43, 
1.34; p=0.3) and metastasis free survival (HR 0.55, 95% CI 0.24, 1.29; p=.2) although these were 
not significant.
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Conclusion—Neoadjuvant chemohormonal therapy followed by RP was associated with lower 
observed rates of BCR and metastasis compared to a prostatectomy only group; however these 
results were not significant. Because this treatment strategy has known harms and unproven 
benefit, this strategy should only be instituted in the setting of a clinical trial.
Introduction
Although prostate cancer (PCa) often follows an indolent course, those with high-risk 
features are at significant risk for local and distant progression.1 Although there are many 
definitions for high-risk non-metastatic PCa2, the National Comprehensive Cancer Network 
(NCCN) defines it as having any of the following characteristics; PSA> 20 ng/ml, clinical 
stage ≥T3, or Gleason grade ≥8.3 Radical prostatectomy (RP) or radiation therapy alone may 
provide benefit but many develop recurrence and progress from their disease.2
Multi-modality approaches have been explored in attempts to reduce rates of failure after 
monotherapy. Trials combining radiation therapy with neoadjuvant, concurrent and adjuvant 
hormonal therapy have demonstrated survival advantages over radiation alone4 but similar 
results with RP have not been observed.5-7 Regardless, surgery remains an attractive option 
for high-risk patients because it may treat or prevent obstructive symptoms, it may more 
readily lend itself to salvage modalities, and it allows more accurate pathologic and nodal 
staging. Additionally approaches combining surgery with neoadjuvant chemotherapy is the 
favored treatment for various other urologic and non-urologic malignancies cancers such as 
bladder8, testicular9, breast10 and esphogeal11 cancer.
In an attempt to improve oncologic outcomes multiple small studies have investigated the 
feasibility and pathologic outcomes of combined chemohormonal therapy (CHT) followed 
by RP in patients with high-risk PCa.12-17 The goal of such an approach is to obtain optimal 
local control while also addressing the potential metastatic component of the disease. 
However because of its long natural history, the therapeutic effect of such trials may not be 
fully realized in these prior studies with short to intermediate follow-up. Furthermore such 
studies are limited due to the lack of a comparison group. Herein, we report long term 
follow up of a previously reported phase II trial of patients with high-risk PCa treated with 
neoadjuvant CHT followed by RP and compared their outcomes to a group of patients from 
a similar timeframe who met oncologic inclusion criteria but underwent RP only.18
METHODS
Study Design
We previously reported on 36 patients enrolled in an IRB approved, non-randomized, 
multicenter phase I/II study to determine the feasibility and safety of neoadjuvant 
estramustine, paclitaxel and carboplatin (4 to 6 cycles of paclitaxel and carboplatin and 
estramustine with concurrent goserelin acetate depot subcutaneously every 3 months during 
chemotherapy) followed by RP.18 The study was conducted between 1997 and 2000 and 
early outcomes were reported in 2004.18 In this current study we omitted two patients with a 
history of treatment for non-genitourinary pelvic malignancies prior to the start of CHT 
therapy, leaving a total of 34 patients in the analysis. Criteria for enrollment included the 
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presence of noncastrate, non-metastatic PCa high-risk PCa, consistent with the NCCN 
guidelines and defined as any of the following; PSA> 20 ng/ml, clinical stage ≥T3, or 
Gleason grade ≥8. Complete inclusion/exclusion criteria are reported elsewhere.18
To determine if neoadjuvant CHT therapy improved outcomes in this cohort, we identified a 
comparison group of 123 consecutive patients who met the oncologic eligibility criteria in 
the original trial, but received no neoadjuvant therapy (neither chemotherapy nor androgen 
deprivation) and underwent RP only at Memorial Sloan-Kettering Cancer Center from 
1996-2001. Because of the likely bias to enroll the highest risk patients into the CHT trial 
we further identified a subgroup within the comparison group at the top 30% of the Kattan 
risk score, as a higher-risk comparison group.19, 20 Patients in both the experimental and 
comparison group were offered additional adjuvant therapy and treated in a similar manner 
if they developed evidence of recurrent or systemic disease.
Statistical Methods
To test for differences in baseline patient and disease characteristics between patients treated 
with CHT plus RP and patients treated with RP alone Wilcoxon rank sum and Fisher's exact 
tests were used. Cox proportional hazard models were used to compare the risk of BCR and 
development of metastasis between the two groups with date of surgery as time zero, with 
adjustment for the Kattan nomogram risk score (predicted risk of BCR within 5 years) for 
risk adjustment. For this study BCR was defined as a PSA >0.05 ng/ml following radical 
prostatectomy. This model was repeated comparing the experimental cohort to the higher-
risk comparison group. As an additional sensitivity analysis, we considered that patients in 
the CHT group had delayed surgery because of the time required for neoadjuvant therapy. 
Consider a patient with occult metastasis destined to produce sufficient PSA to be detectable 
two years after diagnosis irrespective of treatment. Such a patient would have an apparently 
shorter time from surgery to BCR if surgery was delayed by CHT. To control for this effect, 
we used a previously published methodology.21 The outcomes were dichotomized into event 
before or after five years, with patients censored before five years excluded. A logistic 
regression model was then built, adjusted for Kattan nomogram risk score. All analysis were 
conducted using Stata 12.0 (Stata Corp., College Station, Tx). Two patients with no follow-
up were omitted from the biochemical recurrence analysis (one in each treatment group), 
and one patient with no follow-up (control group) was omitted from the metastatic disease 
analysis. All patients were included in overall survival analysis.
Results
Patient and disease characteristics for both the treatment group and the control group are 
presented in table 1. Patients receiving CHT were younger than those undergoing RP alone 
and at much higher baseline risk from their disease as reflected by a nomogram risk of BCR 
scores 33 percentage points higher than those treated with RP alone (p<0.0001). Median 
total PSA was 18.5 ng/ml higher than patients undergoing RP alone (p<0.0001) and 55% of 
those enrolling in the protocol were clinical stage ≥T3 versus 12% of those undergoing RP 
alone (p<0.0001). Even for a subset of control group at the top 30% of the Kattan risk score, 
important differences remained in total PSA levels and clinical stage. Pathologic 
comparisons demonstrate that despite worse pretreatment features, the CHT group had a 
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lower proportion of positive surgical margins and lymph node invasion. Although a higher 
percentage of patients in this group had extraprostatic extension, seminal vesicle invasion, 
and bladder neck invasion.
Median follow up for BCR-free patients was 11.2 and 12.3 years for those treated with RP 
alone and CHT plus RP, respectively. BCR was present in 73 of 122 patients in the RP only 
group and 24 of 33 patients in the CHT plus RP group during the entire follow up; 60 and 24 
within 5 years respectively. Differences between groups were small and non-significant, and 
the direction of effect was sensitive to the statistical method used (Table 2). Similarly 
survival curves adjusted for Kattan risk failed to demonstrate significant differences between 
groups (Figure 1).
During follow-up 31 patients who underwent RP only developed metastatic PCa and 13 
patients in the CHT plus RP developed metastatic disease; 19 and 6 within 5 years, 
respectively. The risk of metastasis was importantly lower in the CHT + RP group, with 
similar findings for the four different analyses. Nonetheless, confidence intervals are wide 
and no result was statistically significant.
For patients who received CHT prior to RP, probability of disease-specific survival at 10 
years was 84% (95% CI 66%, 93%) and overall survival was 78% (95% CI 60%, 89%). 
Overall survival favored the CHT group over the comparison group when adjusted for 
differences in disease characteristics; again these analyses demonstrated wide confidence 
intervals and no statistically significant results. Three patients in the RP only group, and one 
in the RP plus CHT group, experienced symptomatic local recurrences that required 
intervention.
Discussion
We report long term outcomes of patients enrolled in a phase II trial of neoadjuvant CHT 
followed by RP for the treatment of high-risk PCa. Patients had promising long term overall 
oncologic outcomes, with only one patient developing a symptomatic local recurrence, and 
few prostate cancer specific deaths. In order to better understand the impact of the CHT plus 
RP, we have attempted to compare the trial patients to a cohort of patients from the same 
time frame whose clinical variables made them potential candidates for enrollment in the 
trial but instead received RP alone as their primary treatment. Despite both groups being 
defined as high-risk by NCCN criteria, the CHT group had markedly higher baseline risk, 
confirming that “high-risk” prostate cancer includes patients at very different levels of risk.2 
After adjustment for baseline risk, we observed a potential beneficial effect of the CHT 
strategy which demonstrated lower rates of metastases; confidence intervals were wide and 
none of these findings were statistically significant.
Taxane based chemotherapy has improved survival for patients with castrate-resistant, 
metastatic prostate cancer and remains the primary cytotoxic agent used for the treatment of 
this disease.19,20 Several investigators have attempted to evaluate the impact of neoadjuvant 
taxane based CHT followed by RP for high-risk PCa with the hypothesis that this approach 
may help extirpate tumor cells that are no longer confined to the prostate. Existing studies 
have primarily focused on the feasibility, toxicities and pathologic response rate with 
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secondary outcome measures being short to intermediate BCR rates; our study is unique and 
important in that it is by far the longest follow of any such cohort and our outcome measures 
include metastasis free and overall survival which has not been examined in previous 
studies. Prior investigators have demonstrated that complete pathologic response occurs 
infrequently (0 – 11%) with encouraging but short-term BCR rates.12-18 Prayer-Galetti et al. 
reported a phase II trial of 21 patients who received androgen deprivation therapy (ADT) 
and four cycles of docetaxel plus estramustine followed by RP; pT0 was rate (5%) and with 
a median follow-up of 53 months, eight patients (42%) remained disease-free, nine (47%) 
had biochemical recurrence only and two (11%) had local recurrence.13 Sella et al. 
examined 22 patients who similarly received ADT and four cycles of docetaxel and 
estramustine however they found no patients had a complete pathologic response and with a 
median follow-up of 23.6 months 45% of patients had developed BCR.14 Chi et al. 
described the results of a phase II multicenter study of 64 patients who completed ADT and 
three cycles of docetaxel prior to RP; two patients (3%) had complete pathologic response 
and 30% experienced BCR at 42.7 months of follow-up.15 Mellado et al. reported on 51 
patients who received ADT and three cycles of docetaxel followed by RP and demonstrated 
a complete pathologic response in three (6%) patients and BCR in 18 (31.6%) of patients 
with a median follow-up of 35 months.16 Garzotto et al. reported on the results of 57 
patients who received docetaxel and estramustine without ADT prior to RP and 
demonstrated no patients had a complete pathologic response and 5-year BCR- free survival 
was 49.8% (95% CI, 35.5%- 64.1%).17 Variations in outcomes between studies may be 
attributable to differences in patients initial disease risk, type and duration of cytotoxic 
agents used, length of follow or use of ADT. In our original report in 2004 we demonstrated 
similar findings to these other cohorts; no patient achieved a pathologic complete response 
(0% pT0) and BCR rates were 51% with a median follow up of 20 months.18 Importantly in 
our study with longer follow, only 7 of 31 patients (22%; 95% CI 10%, 37%) remain free of 
BCR within 10 years of RP.
Prior randomized trials comparing RP alone to neoadjuvant ADT followed by RP without 
concomitant chemotherapy, have demonstrated decreased rates of margin positivity and 
tumor down staging but have repeatedly failed to establish improved oncologic outcomes.5-7 
This exemplifies why pathologic and early outcomes must be followed with long term 
results focused on more meaningful oncologic endpoints and to our knowledge this is the 
first report of the long-term outcomes of neoadjuvant CHT followed by RP. Although not 
the primary endpoint of this phase II study we have demonstrated low rates of metastasis 
with CHT followed by RP; with 10 years of follow up, 63% (95% CI 44%, 77%) patients in 
the experimental group developed metastatic disease. Adjusted for baseline risk score, rates 
of metastatic disease in the CHT group were lower than those in our comparison group but 
the difference was not statistically significant. Additionally despite the aggressive nature of 
their malignancy only 16% (95% CI 7%, 34%) died from their disease and 22% (95% CI 
11%, 40%) from any cause in the experimental group.
While we attempted comparisons between patients enrolled in this phase II trial and a group 
of patients whose clinical characteristics would have allowed them entry into the study and 
were treated during a similar timeframe, these comparisons were limited due to the large 
baseline differences in these groups. Such comparisons may provide insight into the impact 
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of the experimental intervention but have important flaws as exemplified in this study. The 
experimental group had both more aggressive clinical characteristics and despite receiving 
neoadjuvant CHT retained more aggressive pathologic features. It is likely that in addition to 
these observed differences there may be unobserved differences between these groups 
further limiting these findings. Currently studies such as the Cancer and Leukemia Group B 
randomized phase III study of RP alone versus docetaxel-based CHT before RP are accruing 
patients in an effort to better assess the impact of neoadjuvant chemo-hormonal treatment 
before surgery; however long term oncologic comparisons are many years away.21
Neoadjuvant chemo-hormonal therapy followed by RP is yet to be established as superior to 
RP alone yet it is associated with adverse toxicities. While generally well tolerated with 
almost all patients completing the planned neoadjuvant therapies in this and other studies, 
both docetaxel and hormonal agents may have adverse side effects. Chi et al. reported thirty 
grade 3 or 4 adverse events related to protocol therapy in their study of 72 men14 and in the 
original report of our series deep venous thrombosis occurred in 8 (22%) of patients.15 
Additionally despite protocol mandated recording of adverse events these studies may not 
fully capture common adverse effects of androgen deprivation that may negatively impact 
quality of life such as, decreased libido, erectile dysfunction, vasomotor symptoms, 
impairment of cognitive function, and risk of osteoporosis. Hormonal therapy may also 
induce a desmoplastic reaction and make surgery more difficult.22,23 In the future, patient 
reported outcomes would be essential component of these trials.24
In addition to the lack of an adequate comparison group in this study, it is limited by its 
small size. The central estimate for the effects of neoadjuvant therapy on metastasis was an 
approximate halving of risk, a large effect of clear clinical relevance, yet one that was not 
statistically in our analysis. Other limitations include that complete data was not available 
for all patients, and we attempted to address endpoints that were not the goal of the original 
study. Patients received a variety of treatments for BCR and metastatic disease that 
generally included hormonal therapy as well as additional treatments but these were not 
standardized and changed over the course of the study as new therapies emerged. These 
treatments may have impacted cancer specific and overall survival.
Conclusion
This is the first report of long term outcomes of neoadjuvant cytotoxic chemotherapy 
combined with hormonal therapy followed by RP. High-risk PCa patients treated with 
neoadjuvant CHT followed by RP experienced a trend toward improvement in metastatic-
free and overall survival when compared with a group of high-risk patients undergoing RP 
alone; however this trend did not reach significance. Neoadjuvant chemo-hormonal therapy 
is associated with a number of risks and as of yet has not shown a significant clinical 
benefit. Patients with high-risk PCa should only pursue neoadjuvant strategies, prior to RP, 
in the setting of clinical trial; such trials are open and actively accruing patients.
Key of Definitions and abbreviations
RP Radical Prostatectomy
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NCCN National Comprehensive Cancer Network
CHT Chemohormonal therapy
PCa Prostate Cancer
ADT Androgen Depravation Therapy
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Biochemical recurrence-free probability for patients treated for high-risk prostate cancer 
treated with chemohormonal therapy and RP in a phase II multicenter trial (solid, n=33) 
compared to patients treated with RP alone (dashed, n=122), adjusted for the Kattan risk 
score (HR 0.76, 95% CI 0.43, 1.34; p=0.3).
Silberstein et al. Page 9










Metastatic disease-free probability for patients treated for high-risk prostate cancer treated 
with chemohormonal therapy and RP in a phase II multicenter trial (solid, n=34) compared 
to patients treated with RP alone (dashed, n=122) , adjusted for the Kattan risk score (HR= 
0.55, 95% CI 0.24, 1.29; p=.2).
Silberstein et al. Page 10

















Silberstein et al. Page 11
Table 1
Patient and disease characteristics of prostate cancer patients treated with chemohormonal therapy (CHP) and 
radical prostatectomy (RP) vs those eligible for enrollment but underwent RP only. CHT patients were also 
compared to a high-risk RP subset of the comparison group at the top 30% of the Kattan risk score. Data 
presented are median (IQR) or frequency (%).
CHT + RP (n=34) RP Only (n=123) p-value High Risk RP (N=37) p-value
Clinical Risk Factors
    Age at diagnosis 56.0 (51.0, 61.0) 60.8 (55.5, 64.9) 0.002 57.6 (55.0, 62.7) 0.2
    Total PSA 27.7 (11.0, 43.2) 9.2 (5.5, 20.0) <0.0001 16.8 (10.1, 23.0) 0.017
    Predicted 5-year risk of BCR* 69.1 (54.5, 90.2) 36.2 (25.2, 50.9) <0.0001 68.1 (52.1, 72.2) 0.091
    Clinical Stage
        T1c/T2a 12 (35%) 66 (54%) <0.0001 6 (16%) 0.002
        T2b/T2c 4 (9%) 42 (34%) 17 (46%)
        T3a/T3b 18 (53%) 15 (12%) 14 (38%)
Biopsy Gleason Score
        <7 2 (6%) 16 (13%) 0.005 4 (11%) 0.7
        7 17 (53%) 27 (22%) 21 (57%)
        >=8 14 (41%) 80 (65%) 12 (32%)
Pathologic Outcomes
    Extracapsular Extension 34 (100%) 70 (57%) 25 (68%)
    Seminal Vesicle Invasion 20 (59%) 31 (25%) 14 (38%)
    Bladder Neck Invasion 8 (24%) 10 (8.1%) 6 (16%)
    Positive Surgical Margins 8 (24%) 47 (38%) 17 (46%)
    Positive Nodes 2 (5.9%) 16 (13%) 8 (22%)
    Pathological stage
        T2a 2 (5.9%) 10 (8.1%) 1 (2.7%)
        T2b/T2c 9 (26%) 39 (32%) 8 (22%)
        T3a/T3b 16 (47%) 64 (52%) 22 (59%)
        T4 7 (21%) 10 (8.1%) 6 (16%)
    Pathologic Gleason Score
        Not graded due to CHT 23 (68%) 0 0
        6 1 (9.1%) 8 (6.5%) 2 (5.4%)
        7 4 (36%) 62 (50%) 20 (54%)
        8 1 (9.1%) 28 (23%) 7 (19%)
        9 5 (45%) 25 (20%) 8 (22%)
Postoperative Treatment
    Adjuvant Treatment 3 (9.1%) 1 (1.7%) 1 (5.9%)
    Salvage XRT within 5 years 3 (8.8%) 26 (21%) 5 (14%)
*
Based on the Kattan Nomogram (Gleason grade, clinical stage and PSA)
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Table 2
Outcomes for patients treated with chemohormonal therapy (CHT) and RP (N=34) compared with patients 
eligible for enrollment in the CHT trial but underwent RP only (N=123). Because of imbalances in the two 
groups the CHT were also compared to a subset of the comparison group at the top 30% of the Kattan risk 
score (N=37).
Outcome Comparison Group Cox Proportional Hazard Model 5-yr Logistic Regression Model
HR 95% CI p-value OR 95% CI p-value
BCR Complete 0.76 0.43, 1.34 0.3 1.02 0.35, 2.95 1
BCR High-risk only 0.83 0.47, 1.48 0.5 1.42 0.46, 4.40 0.5
Metastatic Disease Complete 0.55 0.24, 1.29 0.2 0.37 0.10, 1.31 0.12
Metastatic Disease High-risk only 0.59 0.25, 1.41 0.2 0.43 0.12, 1.47 0.2
Overall Death Complete 0.98 0.41, 2.35 1 0.42 0.07, 2.62 0.4
Overall Death High-risk only 0.99 0.40, 2.45 1 0.41 0.07, 2.32 0.3
* BCR = Biochemical Recurrence
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